Key result
Higher admission total bilirubin is linked to ~174% greater MACCE risk in new-onset NSTEMI.
Why the study?
The potential prognostic role of total bilirubin in patients with new-onset NSTEMI is not fully understood.
Does higher admission serum total bilirubin predict major adverse cardiac and cerebrovascular events in patients with new-onset NSTEMI?
Cohort (n=327)
No
Does higher admission serum total bilirubin predict major adverse cardiac and cerebrovascular events in patients with new-onset NSTEMI?
Hazard Ratio: 2.737 (95% CI 1.161–6.45)
p-value: p=<0.05
Higher admission serum total bilirubin levels are independently associated with greater coronary lesion severity and an increased long-term risk of major adverse cardiac and cerebrovascular events in patients with new-onset NSTEMI.
May flag higher MACCE risk in new-onset NSTEMI; hypothesis-generating and should not yet change practice.
Background: The potential prognostic role of total bilirubin (TBIL) in patients with new-onset non-ST elevation myocardial infarction (NSTEMI) is not fully understood. This study aims to evaluate the potential predictive value of TBIL for long-term prognosis in patients with new-onset NSTEMI.Methods: Patients with new-onset NSTEMI that underwent emergency coronary angiography in our department from June 2015 to March 2020 were included. Baseline TBIL was measured at admission. SYNTAX scores were used to indicate the severity of coronary lesions. The association between TBIL and SYNTAX scores was analyzed using multivariate logistic regression. The patients were followed for the incidence of major adverse cardiac and cerebrovascular events (MACCEs). The association between TBIL and MACCEs was analyzed using Kaplan–Meier survival methods.Results: In total 327 patients were included in this study. Patients were divided according to tertiles of TBIL (first tertile <10.23 µmol/L, n = 109; second tertile 10.23–14.30 µmol/L, n = 109; and third tertile ≥14.30 µmol/L, n = 109). TBIL was independently associated with the severity of coronary lesions in patients with NSTEMI, with an adjusted odds ratio (OR) and 95% confidence interval (CI) for the third tertile and the second tertile compared with the first tertile of TBIL of 2.259 (1.197-4.263) and 2.167 (1.157-4.059), respectively (both p<0.05). After a mean follow-up of 30.33 months, MACCE had occurred in 57 patients. TBIL was independently associated with the increased risk of MACCEs, with an adjusted hazard ratio (HR) and 95% CI for the third tertile and the second tertile compared with the first tertile of TBIL of 2.737 (1.161 -6.450) and 3.272 (1.408-7.607), respectively (both p<0.05).Conclusions: Higher myocardial infarction admission TBIL might independently predict poor prognosis in patients with NSTEMI.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2021) conducted a cohort in New-onset non-ST elevation myocardial infarction (NSTEMI) (n=327). Serum total bilirubin (TBIL) vs. First tertile of TBIL (<10.23 µmol/L) was evaluated on Major adverse cardiac and cerebrovascular events (MACCEs) (HR 2.737, 95% CI 1.161-6.450, p=<0.05). Higher admission serum total bilirubin (≥14.30 µmol/L) was independently associated with an increased risk of major adverse cardiac and cerebrovascular events (HR 2.737) compared to lower levels in patients with new-onset NSTEMI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: